Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer.

Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2009 Jul 10;27(20):3297-302. doi: 10.1200/JCO.2009.19.6410. Epub 2009 Jun 1.

PMID:
19487376
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Metformin in breast cancer: time for action.

Goodwin PJ, Ligibel JA, Stambolic V.

J Clin Oncol. 2009 Jul 10;27(20):3271-3. doi: 10.1200/JCO.2009.22.1630. Epub 2009 Jun 1. No abstract available.

PMID:
19487373
[PubMed - indexed for MEDLINE]
3.

Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer.

Bayraktar S, Hernadez-Aya LF, Lei X, Meric-Bernstam F, Litton JK, Hsu L, Hortobagyi GN, Gonzalez-Angulo AM.

Cancer. 2012 Mar 1;118(5):1202-11. doi: 10.1002/cncr.26439. Epub 2011 Jul 28.

PMID:
21800293
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Clinical pathological characteristics and prognostic analysis of 1,013 breast cancer patients with diabetes.

Hou G, Zhang S, Zhang X, Wang P, Hao X, Zhang J.

Breast Cancer Res Treat. 2013 Feb;137(3):807-16. doi: 10.1007/s10549-012-2404-y. Epub 2013 Jan 6.

PMID:
23292119
[PubMed - indexed for MEDLINE]
5.

Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer.

Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM.

J Clin Oncol. 2011 Jul 1;29(19):2645-52. doi: 10.1200/JCO.2010.33.4441. Epub 2011 May 31.

PMID:
21632501
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Metformin use and improved response to therapy in rectal cancer.

Skinner HD, Crane CH, Garrett CR, Eng C, Chang GJ, Skibber JM, Rodriguez-Bigas MA, Kelly P, Sandulache VC, Delclos ME, Krishnan S, Das P.

Cancer Med. 2013 Feb;2(1):99-107. doi: 10.1002/cam4.54. Epub 2013 Feb 3.

PMID:
24133632
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.

Gajdos C, Tartter PI, Estabrook A, Gistrak MA, Jaffer S, Bleiweiss IJ.

J Surg Oncol. 2002 May;80(1):4-11.

PMID:
11967899
[PubMed - indexed for MEDLINE]
8.

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy.

Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE.

J Clin Oncol. 1999 Feb;17(2):460-9.

PMID:
10080586
[PubMed - indexed for MEDLINE]
9.

Metformin as an addition to conventional chemotherapy in breast cancer.

Grenader T, Goldberg A, Shavit L.

J Clin Oncol. 2009 Dec 10;27(35):e259; author reply e260. doi: 10.1200/JCO.2009.25.4110. Epub 2009 Nov 2. No abstract available.

PMID:
19884518
[PubMed - indexed for MEDLINE]
10.

Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer.

Chavez-Macgregor M, Brown E, Lei X, Litton J, Meric-Bernstram F, Mettendorf E, Hernandez L, Valero V, Hortobagyi GN, Gonzalez-Angulo AM.

Cancer. 2012 Jan 15;118(2):326-32. doi: 10.1002/cncr.26144. Epub 2011 May 16.

PMID:
21590688
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.

Untch M, Fasching PA, Konecny GE, Hasmüller S, Lebeau A, Kreienberg R, Camara O, Müller V, du Bois A, Kühn T, Stickeler E, Harbeck N, Höss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S.

J Clin Oncol. 2011 Sep 1;29(25):3351-7. doi: 10.1200/JCO.2010.31.4930. Epub 2011 Jul 25.

PMID:
21788566
[PubMed - indexed for MEDLINE]
12.

Predictive factors of pathologic complete response and clinical tumor progression after preoperative chemotherapy in patients with stage II and III breast cancer.

Jeong JH, Jung SY, Park IH, Lee KS, Kang HS, Kim SW, Kwon Y, Kim EA, Ko KL, Nam BH, Lee S, Ro J.

Invest New Drugs. 2012 Feb;30(1):408-16. doi: 10.1007/s10637-010-9555-7. Epub 2010 Oct 5.

PMID:
20922557
[PubMed - indexed for MEDLINE]
13.

Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer.

Klubo-Gwiezdzinska J, Costello J Jr, Patel A, Bauer A, Jensen K, Mete M, Burman KD, Wartofsky L, Vasko V.

J Clin Endocrinol Metab. 2013 Aug;98(8):3269-79. doi: 10.1210/jc.2012-3799. Epub 2013 May 24.

PMID:
23709654
[PubMed - indexed for MEDLINE]
14.

Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.

Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J.

Cancer. 2010 Sep 15;116(18):4227-37. doi: 10.1002/cncr.25309.

PMID:
20549829
[PubMed - indexed for MEDLINE]
Free Article
15.

Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer.

Hayashi M, Yamamoto Y, Ibusuki M, Fujiwara S, Yamamoto S, Tomita S, Nakano M, Murakami K, Iyama K, Iwase H.

Ann Surg Oncol. 2012 Sep;19(9):3042-9. doi: 10.1245/s10434-012-2343-1. Epub 2012 Apr 3.

PMID:
22476757
[PubMed - indexed for MEDLINE]
16.

Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage II and stage III breast cancer.

Petrarca CR, Brunetto AT, Duval V, Brondani A, Carvalho GP, Garicochea B.

Clin Breast Cancer. 2011 Apr;11(2):129-34. doi: 10.1016/j.clbc.2011.03.002. Epub 2011 Apr 11.

PMID:
21569999
[PubMed - indexed for MEDLINE]
17.

Clinical pathological characteristics and prognostic analysis of diabetic women with luminal subtype breast cancer.

Xiao Y, Zhang S, Hou G, Zhang X, Hao X, Zhang J.

Tumour Biol. 2014 Mar;35(3):2035-45. doi: 10.1007/s13277-013-1270-5. Epub 2013 Oct 5.

PMID:
24096546
[PubMed - indexed for MEDLINE]
18.

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.

Darb-Esfahani S, Loibl S, Müller BM, Roller M, Denkert C, Komor M, Schlüns K, Blohmer JU, Budczies J, Gerber B, Noske A, du Bois A, Weichert W, Jackisch C, Dietel M, Richter K, Kaufmann M, von Minckwitz G.

Breast Cancer Res. 2009;11(5):R69. doi: 10.1186/bcr2363. Epub .

PMID:
19758440
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Retrospective analysis of neoadjuvant chemotherapy for breast cancer in Turkish patients.

Duman BB, Afşar ÇU, Günaldi M, Sahin B, Kara IO, Erkisi M, Erçolak V.

Asian Pac J Cancer Prev. 2012;13(8):4119-23.

PMID:
23098527
[PubMed - indexed for MEDLINE]
Free Article
20.

Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.

Arun B, Bayraktar S, Liu DD, Gutierrez Barrera AM, Atchley D, Pusztai L, Litton JK, Valero V, Meric-Bernstam F, Hortobagyi GN, Albarracin C.

J Clin Oncol. 2011 Oct 1;29(28):3739-46. doi: 10.1200/JCO.2011.35.2682. Epub 2011 Sep 6.

PMID:
21900106
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk